Eli Lilly and Company

Get EMGALITY delivered to your door with fast shipping nationwide.

Never wait in line at the pharmacy again.

Patients pay as little as $0 out-of-pocket for EMGALITY.
Eli Lilly and Company will pay the remaining co-payment or cost-sharing obligation per fill.

Once your prescription is transferred, it is shipped in 1-2 days.

Manufacturer Promotional Price



Want FREE shipping? Ask us how to qualify

Select Medication

* Valid prescription required. Patient must meet all eligibility
requirements to apply discount coupon.

Why migraine patients love Truepill

Easy Rx Transfer

A licensed pharmacist will review your information online and transfer your medication automatically.

Fast Shipping

No need to wait in line at a pharmacy. Your FDA-approved medications are delivered straight to your door.

Ongoing Support

Message a pharmacist anytime online for support with your treatment, and get refills delivered automatically.

What people are saying about EMGALITY

Talk to a member
of our team

If you have any questions please contact our care team at (650) 353-5495 or support@truepill.com

We accept your insurance

We accept a wide range of insurance providers. If you have any coverage questions give us a call at (650) 399-9905 or go through the order process and enter your insurance. We will contact you to let you know your copay pricing.


We offer two categories of migraine medications - medications for immediate relief and preventative medications. Your doctor will design a treatment plan tailored to your situation, to reduce the number of migraines you experience each month. Learn more about migraine medications
The initial doctor consult is $20 with or without insurance. For medications, we accept all major insurance plans. Your insurance copays are dependant on your insurance provider. We will run your insurance claim and notify you of your copay before shipping your medications.
Yes, you can purchase the medications your doctor prescribes as part of your treatment plan at our cash price.
We accept all major insurance providers and can run your insurance to tell you what your copay will be. Your copays will always be the exact same as what you pay at your current pharmacy.

We will ask you during your order completion process if you want to use insurance or cash. If you select insurance you can provide your insurance details and we will notify you of your copay pricing. We will also always compare your copay pricing with the cash price of the drug and give you full control to choose how you want to pay for your medication.
Truepill is a licensed U.S. pharmacy and ships to all 50 states and Washington DC. We currently do not ship to Puerto Rico and other U.S. territories.


11 DESCRIPTION Galcanezumab-gnlm is a humanized IgG4 monoclonal antibody specific for calcitonin-gene related peptide (CGRP) ligand. Galcanezumab-gnlm is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. Galcanezumab-gnlm is composed of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains and has an overall molecular weight of approximately 147 kDa. EMGALITY (galcanezumab-gnlm) injection is a sterile, preservative-free, clear to opalescent and colorless to slightly yellow to slightly brown solution, for subcutaneous use available in a single-dose prefilled pen or a single-dose prefilled syringe to deliver 120 mg galcanezumab-gnlm. Each mL is composed of 120 mg galcanezumab-gnlm; L-histidine, USP (0.5 mg); L-histidine hydrochloride monohydrate (1.5 mg); Polysorbate 80, USP (0.5 mg); Sodium Chloride, USP (8.8 mg); Water for Injection, USP. The pH range is 5.3 - 6.3.
5 WARNINGS AND PRECAUTIONS Hypersensitivity Reactions: If a serious hypersensitivity reaction occurs, discontinue administration of EMGALITY and initiate appropriate therapy. Hypersensitivity reactions could occur days after administration, and may be prolonged. (5.1) 5.1 Hypersensitivity Reactions Hypersensitivity reactions (e.g., rash, urticaria, and dyspnea) have been reported with EMGALITY in clinical studies. If a serious or severe hypersensitivity reaction occurs, discontinue administration of EMGALITY and initiate appropriate therapy [see Contraindications (4), Adverse Reactions (6.1), and Patient Counseling Information (17)]. Hypersensitivity reactions can occur days after administration, and may be prolonged.
6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions [see Contraindications (4) and Warnings and Precautions (5.1)] The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in EMGALITY clinical studies were injection site reactions. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in clinical trials of another drug and may not reflect the rates observed in clinical practice. The safety of EMGALITY has been evaluated in 2586 patients with migraine who received at least one dose of EMGALITY, representing 1487 patient-years of exposure. Of these, 1920 patients were exposed to EMGALITY once monthly for at least 6 months, and 526 patients were exposed for 12 months. In placebo-controlled clinical studies (Studies 1, 2, and 3), 705 patients received at least one dose of EMGALITY 120 mg once monthly, and 1451 patients received placebo, during 3 months or 6 months of double-blind treatment [see Clinical Studies (14)]. Of the EMGALITY-treated patients, approximately 85% were female, 77% were white, and the mean age was 41 years at study entry. The most common adverse reaction was injection site reactions. In Studies 1, 2, and 3, 1.8% of patients discontinued double-blind treatment because of adverse events. Table 1 summarizes the adverse reactions that occurred within up to 6 months of treatment in the migraine studies. Table 1: Adverse Reactions Occurring in Adults with Migraine with an Incidence of at least 2% for EMGALITY and at least 2% Greater than Placebo (up to 6 Months of Treatment) in Studies 1, 2, and 3 a Injection site reactions include multiple related adverse event terms, such as injection site pain, injection site reaction, injection site erythema, and injection site pruritus. Adverse Reaction EMGALITY 120 mg Monthly (N=705) % Placebo Monthly (N=1451) % Injection site reactionsa 18 13 6.2 Immunogenicity As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to galcanezumab-gnlm in the studies described below with the incidence of antibodies in other studies or to other products may be misleading. The immunogenicity of EMGALITY has been evaluated using an in vitro immunoassay for the detection of binding anti-galcanezumab-gnlm antibodies. For patients whose sera tested positive in the screening immunoassay, an in vitro ligand-binding immunoassay was performed to detect neutralizing antibodies. In controlled studies with EMGALITY up to 6 months (Study 1, Study 2, and Study 3), the incidence of anti-galcanezumab-gnlm antibody development was 4.8% (33/688) in patients receiving EMGALITY once monthly (32 out of 33 of whom had in vitro neutralizing activity). With 12 months of treatment in an open-label study, up to 12.5% (16/128) of EMGALITY-treated patients developed anti-galcanezumab-gnlm antibodies, most of whom tested positive for neutralizing antibodies. Although anti-galcanezumab-gnlm antibody development was not found to affect the pharmacokinetics, safety or efficacy of EMGALITY in these patients, the available data are too limited to make definitive conclusions.